Showing results (531-540 of 553) with videos related to
Sort By:
Pageof 56
Drugs in Context|September 15, 2025
Real-world analysis of IL-23 inhibitors in patients with moderate-to-severe psoriasis and early musculoskeletal symptomsAnnunziata Dattola, Nicoletta Bernardini, Jasmine Anedda, et al.Drugs in Context|February 9, 2024
Chronic liver disease and management with silymarin: an introductory review of a clinical case collectionFrancesco AngelicoDrugs in Context|March 21, 2024
Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric studyTiago Torres, Paulo Varela, Pedro Mendes Bastos, et al.Drugs in Context|July 11, 2024
What are we doing concretely for the food prevention of cancer? Nutrition between scientific evidence and myopic policiesFrancesco Serra, Riccardo Caccialanza, Paolo PedrazzoliDrugs in Context|July 11, 2024
A prospective, observational, multicentre study to evaluate the efficacy of brivaracetam as adjuvant therapy for epilepsy: The Bravo studyFowzia Siddiqui, Bashir A Soomro, Ehsan U Rehman, et al.Drugs in Context|September 12, 2024
Rapid Efficacy of riSankizumab in pretibial psoriasis invOLVEment: RESOLVENicoletta Bernardini, Nevena Skroza, Laura Atzori, et al.Drugs in Context|October 17, 2024
Fixed-dose combination of calcipotriene/betamethasone dipropionate foam for the management of mild-to-moderate psoriasis in daily clinical practice: a collection of clinical experiencesAnna Campanati, Maria Esposito, Giacomo Caldarola, et al.Drugs in Context|August 12, 2024
New and emerging oral therapies for psoriasisOrhan Yilmaz, João Pedro Pinto, Tiago TorresDrugs in Context|August 12, 2024
Anti-IL-17 monoclonal antibodies and bullous pemphigoid: treatment or causal agents? A case series and review of the literatureAnna Paola Lugli, Giacomo Caldarola, Gennaro Marco Falco, et al.Pageof 56